IRWD

#2692
Ironwood Pharmaceuticals, Inc. - Class A
4.37 USD
+8.17%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
4.37
4.37
Jahresspanne
0.53
5.78
Tagesänderung
+8.17%
Monatliche Änderung
+28.53%
6 month change
+187.50%
Jahresänderung
+482.67%
Vorheriger Schlusskurs
4.04
Eröffnung
4.37
Bid
Ask
Tief
4.37
High
4.37
Volumen
91
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 712.56 M
  • Employee 100
  • Founded 1998
  • CEO N/A
  • Website www.ironwoodpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000GBZ3J2
  • Industry Arzneimittelhersteller – spezialisierte und Generika
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
22.47
Preis-Umsatz-Verhältnis
1.85

Ironwood Pharmaceuticals Inc - Class A

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

Nachrichten